Email this article 
Hide
Show all
Original Research
Development of a clinical prediction rule to diagnose Pneumocystis jirovecii pneumonia in the World Health Organization’s algorithm for seriously ill HIV-infected patients
Submitted: 29 March 2018 | Published: 23 July 2018
About the author(s)
Gary Maartens, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South AfricaAnnemie Stewart, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa
Rulan Griesel, Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa
Andre P. Kengne, Non-Communicable Diseases Research Unit, South African Medical Research Council, South Africa
Felix Dube, Division of Medical Microbiology, Department of Pathology, University of Cape Town, South Africa; National Health Laboratory Service, South Africa
Mark Nicol, Division of Medical Microbiology, Department of Pathology, University of Cape Town, South Africa; National Health Laboratory Service, South Africa
Molebogeng X. Rangaka, Department of Medicine and School of Public Health, University of Cape Town, South Africa; Institute for Global Health, Department of Infection and Population Health, University College London, United Kingdom; IIDMM, University of Cape Town, South Africa
Marc Mendelson, Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, South Africa
Abstract
Background: The World Health Organization (WHO) algorithm for the diagnosis of tuberculosis in seriously ill HIV-infected patients recommends that treatment for Pneumocystis jiroveciipneumonia (PJP) should be considered without giving clear guidance on selecting patients for empiric PJP therapy. PJP is a common cause of hospitalisation in HIV-infected patients in resource-poor settings where diagnostic facilities are limited.
Methods: We developed clinical prediction rules for PJP in a prospective cohort of HIV-infected inpatients with WHO danger signs and cough of any duration. The reference standard for PJP was > 1000 copies/mL of P. jirovecii DNA on real-time sputum polymerase chain reaction (PCR). Four potentially predictive variables were selected for regression models: dyspnoea, chest X-ray, haemoglobin and oxygen saturation. Respiratory rate was explored as a replacement for oxygen saturation as pulse oximetry is not always available in resource-poor settings.
Results: We enrolled 500 participants. After imputation for missing values, there were 56 PJP outcome events. Dyspnoea was not independently associated with PJP. Oxygen saturation and respiratory rate were inversely correlated. Two clinical prediction rules were developed: chest X-ray possible/likely PJP, haemoglobin ≥ 9 g/dL and either oxygen saturation < 94% or respiratory rate. The area under the receiver operating characteristic curve of the clinical prediction rule models was 0.761 (95% CI 0.683–0.840) for the respiratory rate model and 0.797 (95% CI 0.725–0.868) for the oxygen saturation model. Both models had zero probability for PJP for scores of zero, and positive likelihood ratios exceeded 10 for high scores.
Conclusion: We developed simple clinical prediction rules for PJP, which, if externally validated, could assist decision-making in the WHO seriously ill algorithm.
Keywords
Metrics
Total abstract views: 4262Total article views: 3625